Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 9/20 | 0.62 |
| ▸ | TAOK1 | Q7L7X3 | 4/20 | 0.48 |
| ▸ | TAOK3 | Q9H2K8 | 4/20 | 0.48 |
| ▸ | EZH2 | Q15910 | 2/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2988653 | 0.90 | PTGDR2 (0.64) | PTGDR2TAOK1TAOK3EZH2MTNR1A | |
| SCHEMBL2988723 | 0.80 | PTGDR2 (0.60) | PTGDR2EZH2MAPK14 | |
| SCHEMBL2982716 | 0.78 | MAPK14 (0.59) | PTGDR2MAPK14 | |
| SCHEMBL1570418 | 0.76 | PTGDR2 (1.00) | PTGDR2 | |
| SCHEMBL15949534 | 0.75 | PTGDR2 (0.80) | PTGDR2 | |
| SCHEMBL2991405 | 0.74 | PTGDR2 (0.61) | PTGDR2MAPK14 | |
| SCHEMBL1571463 | 0.73 | PTGDR2 (0.85) | PTGDR2 | |
| SCHEMBL2992207 | 0.73 | MAPT (0.52) | PTGDR2MAPK14 | |
| SCHEMBL2986467 | 0.73 | PTGDR2 (0.51) | PTGDR2MAPK14 | |
| SCHEMBL2979609 | 0.73 | PTGDR2 (0.61) | PTGDR2MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492437-B2 | 4-substituted phenoxyphenylacetic acid derivatives | ARRAY BIOPHARMA INC. (US) | 2013-07-23 | — | — | US | claimed |
| US-20120202854-A1 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2012-08-09 | — | — | US | claimed |
| US-8492437-B2 | 4-substituted phenoxyphenylacetic acid derivatives | ARRAY BIOPHARMA INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-8492437-B2 | 4-substituted phenoxyphenylacetic acid derivatives | ARRAY BIOPHARMA INC. (US) | 2013-07-23 | — | — | US | disclosed |
| EP-2057115-B9 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | ARRAY BIOPHARMA INC (US) | 2012-12-26 | — | — | EP | disclosed |
| EP-2057115-B1 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | ARRAY BIOPHARMA INC (US) | 2012-10-03 | — | — | EP | disclosed |
| US-20120202854-A1 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202854-A1 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-8183289-B2 | 4-substituted phenoxyphenylacetic acid derivatives | ARRAY BIOPHARMA INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183289-B2 | 4-substituted phenoxyphenylacetic acid derivatives | ARRAY BIOPHARMA INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183289-B2 | 4-substituted phenoxyphenylacetic acid derivatives | ARRAY BIOPHARMA INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20100173955-A1 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2010-07-08 | — | — | US | disclosed |
| US-20100173955-A1 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2010-07-08 | — | — | US | disclosed |
| US-20100173955-A1 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2010-07-08 | — | — | US | disclosed |
| EP-2057115-A1 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | Array Biopharma, Inc. (US) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008024746-A1 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | ARRAY BIOPHARMA, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173955-A1 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | CD22, HRH2, CD74 | PTGDR2 12/4885TAOK1 4613/4885TAOK3 4442/4885 |
| US-20120202854-A1 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | CD22, HRH2, CD74 | PTGDR2 12/4885TAOK1 4613/4885TAOK3 4442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.